This is therefore a comparing of the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation in Eli Lilly and Company (NYSE:LLY) and AbbVie Inc. (NYSE:ABBV). The two are both Drug Manufacturers Major companies that compete with one another.
Valuation & Earnings
Table 1 showcases the gross revenue, earnings per share and valuation of Eli Lilly and Company and AbbVie Inc. AbbVie Inc. appears to has lower revenue, but higher earnings than Eli Lilly and Company. Business that currently has a higher P/E ratio means that it is the more expensive of the two businesses. Eli Lilly and Company is currently more expensive than AbbVie Inc., because its trading at a higher P/E ratio.
Profitability
Table 2 demonstrates the return on equity, net margins and return on assets of Eli Lilly and Company and AbbVie Inc.
Risk & Volatility
A beta of 0.18 shows that Eli Lilly and Company is 82.00% less volatile than Standard & Poors 500. AbbVie Inc.s 8.00% less volatile than Standard & Poors 500 volatility due to the companys 0.92 beta.
Liquidity
Eli Lilly and Companys Current Ratio and Quick Ratio are 1.1 and 0.8 respectively. The Current Ratio and Quick Ratio of its competitor AbbVie Inc. are 1 and 0.9 respectively. Eli Lilly and Company therefore has a better chance of paying off short and long-term obligations compared to AbbVie Inc.
Analyst Ratings
The Recommendations and Ratings for Eli Lilly and Company and AbbVie Inc. are featured in the next table.
The consensus target price of Eli Lilly and Company is $130.25, with potential upside of 17.08%. Competitively AbbVie Inc. has an average target price of $81.33, with potential downside of -0.62%. The data from earlier shows that analysts view suggest that Eli Lilly and Company seems more appealing than AbbVie Inc.
Insider and Institutional Ownership
Institutional investors owned 83.7% of Eli Lilly and Company shares and 71% of AbbVie Inc. shares. Eli Lilly and Companys share owned by insiders are 12.1%. Insiders Comparatively, owned 0.1% of AbbVie Inc. shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year Eli Lilly and Companys stock price has smaller decline than AbbVie Inc.
Summary
Eli Lilly and Company beats on 10 of the 15 factors AbbVie Inc.
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine headaches. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, and heartworm diseases, as well as controls intestinal parasite infections. Additionally, the company offers vaccinev to prevent Lyme disease, bronchial infections, rabies, and various infectious diseases in dogs, cats, and horses. It has collaboration agreements with Daiichi Sankyo Co., Ltd., Incyte Corporation, Pfizer Inc., AstraZeneca, William Sansum Diabetes Center, Purdue University, and Nektar Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinsons disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
View original post here:
Eli Lilly and Company (LLY) and AbbVie Inc. (NYSE:ABBV) Contrasting side by side - FinanceMercury
